Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Receives $36.50 Average PT from Analysts

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have been assigned a consensus rating of “Hold” from the eight research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $36.50.

A number of research firms recently issued reports on LKFT. Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, May 26th. Finally, Wall Street Zen cut shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

A number of institutional investors have recently added to or reduced their stakes in LKFT. Ameriprise Financial Inc. increased its position in Lakefront Biotherapeutics American Depositary Shares by 2,490.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,416,934 shares of the biotechnology company’s stock worth $49,083,000 after purchasing an additional 1,362,229 shares in the last quarter. UBS Group AG grew its holdings in Lakefront Biotherapeutics American Depositary Shares by 128.4% during the 4th quarter. UBS Group AG now owns 349,444 shares of the biotechnology company’s stock worth $11,427,000 after acquiring an additional 196,445 shares during the last quarter. Millennium Management LLC increased its position in Lakefront Biotherapeutics American Depositary Shares by 121.9% in the 4th quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock valued at $11,097,000 after acquiring an additional 186,452 shares during the period. Jane Street Group LLC increased its position in Lakefront Biotherapeutics American Depositary Shares by 2,245.7% in the 1st quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock valued at $2,783,000 after acquiring an additional 115,946 shares during the period. Finally, Kotler Kevin acquired a new position in Lakefront Biotherapeutics American Depositary Shares in the 4th quarter valued at approximately $2,943,000. 32.46% of the stock is currently owned by institutional investors and hedge funds.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

Shares of NASDAQ:LKFT opened at $29.48 on Monday. The firm has a 50 day moving average of $28.18 and a 200-day moving average of $30.97. The stock has a market capitalization of $1.94 billion, a PE ratio of -20.91 and a beta of 0.26. Lakefront Biotherapeutics American Depositary Shares has a 12 month low of $26.42 and a 12 month high of $37.78.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share (EPS) for the quarter. The company had revenue of $1.06 billion for the quarter. On average, research analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.